First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

Home   |   Publication   |   First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
Publications
75 +
Clinical Trials Ran
0 +
Approved Therapies
0

Areas of Expertise